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Efavirenz (EFZ) has been associated with neuropsychiatric side effects. Recently, the 8-hydroxy-EFZ (8OH-EFZ) metabolite has
been shown to be a potent neurotoxin in vitro, inducing neuronal damage at concentrations of 3.3 ng/ml. EFZ induced similar
neuronal damage at concentrations of 31.6 ng/ml. We investigated the effect of genotype and blood-brain barrier integrity on
EFZmetabolite concentrations in cerebrospinal fluid (CSF). Wemeasured CSF drug concentrations in subjects from two sepa-
rate study populations: 47 subjects with tuberculous meningitis (TBM) coinfection in Vietnam receiving 800 mg EFZ with stan-
dard antituberculous treatment and 25 subjects from the PARTITION study in the United Kingdomwithout central nervous
system infection receiving 600 mg EFZ. EFZ andmetabolite concentrations in CSF and plasma were measured and compared
with estimates of effectiveness and neurotoxicity from available published in vitro and in vivo data. The effect of the CYP2B6
c.516G¡T genotype (GG genotype, fast EFVmetabolizer status; GT genotype, intermediate EFVmetabolizer status; TT geno-
type, slow EFVmetabolizer status) was examined. The mean CSF concentrations of EFZ and 8OH-EFZ in the TBM group were
60.3 and 39.3 ng/ml, respectively, and those in the no-TBM group were 15.0 and 5.9 ng/ml, respectively. Plasma EFZ and 8OH-
EFZ concentrations were similar between the two groups. CSF EFZ concentrations were above the in vitro toxic concentration in
76% of samples (GG genotype, 61%; GT genotype, 90%; TT genotype, 100%) in the TBM group and 13% of samples (GG geno-
type, 0%; GT genotype, 18%; TT genotype, 50%) in the no-TBM group. CSF 8OH-EFZ concentrations were above the in vitro
toxic concentration in 98% of the TBM group and 87% of the no-TBM group; levels were independent of genotype but correlated
with the CSF/plasma albumin ratio. Potentially neurotoxic concentrations of 8OH-EFZ are frequently observed in CSF indepen-
dently of the CYP2B6 genotype, particularly in those with impaired blood-brain barrier integrity.
Despite concerns over central nervous system (CNS) toxicity,efavirenz (EFZ) is widely deployedwithin first-line combina-
tion HIV treatment regimens worldwide because of its effective-
ness, established safety record, and resilience to hepatic enzyme
induction by rifampin in patients who require concomitant ther-
apy against tuberculosis (TB) (1, 2). EFZ undergoes rapid absorp-
tion, with maximum plasma concentrations being reached in 3 to
6 h and therapeutic levels being achieved within a few days of the
commencement of treatment (3). There is large interindividual
variability in EFZ pharmacokinetics (4–7), placing patients with
low plasma concentrations at risk of losing virological control and
developing resistance and those with high plasma concentrations
at risk of developing adverse effects (8, 9). EFZ is primarily me-
tabolized by cytochromeP450CYP2B6 to yield themost abundant
metabolite, 8-hydroxy-EFZ (8OH-EFZ). Comparatively minor
alternative metabolic pathways are through CYP2A6 (leading to
the 7OH-EFZ metabolite) and CYP3A (10).
EFZ plasma concentrations relate strongly to the genetic poly-
morphism in CYP2B6 metabolism (11–15), including the most
commonly studied CYP2B6 single nucleotide polymorphism
c.516G¡T (rs3745274), which encodes a Gln172His amino acid
substitution. The CYP2B6 c.516G¡T GG genotype is associated
with a fast EFV metabolizer status, the GT genotype is associated
with an intermediate metabolizer status, and the TT genotype is
associated with a slow metabolizer status. Preliminary data sug-
gest that in CYP2B6 slow metabolizers, CYP2A6 represents the
dominant route of elimination and may be affected by enzyme
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inhibition through concomitant isoniazid administration (16).
This may have pharmacogenetic implications, as CYP2A6 has
considerable copy number variation in Southeast Asian popula-
tions (17). The effect of theCYP2A6 copynumber onCSFEFZ and
metabolite concentrations in those with and without slow
CYP2B6metabolizer status is not known.
The results of in vitro experiments indicate that 8OH-EFZ is
associated with cytotoxicity via stimulation of mitochondrial dys-
function and stress-activated signaling pathways (18). In addition,
8OH-EFZ has been shown to be prone to oxidative degradation
with potentially toxic quinone-imine derivatives (19). Recently,
8OH-EFZ was shown to be neurotoxic in vitro at a concentration
similar to the concentrations found in cerebrospinal fluid (CSF)
(20). That study demonstrated that 8OH-EFZ concentrations of
just 3.3 ng/ml caused neuronal damage, inducing calcium flux,
apoptosis, and considerable damage to dendritic spines. These
changes were not observed for EFZ or 7OH-EFZ at this level.
Concentrations of EFZ and 7OH-EFZ approximately 10 times the
concentration of 8OH-EFZ were required to induce similar dam-
age. The role of 8OH-EFZ in EFZ-associated CNS toxicity has not
been elucidated.
In this study, we developed sensitive, accurate, and precise as-
says for measuring EFZ and its metabolites in CSF. We aimed to
characterize the disposition of EFZ and its metabolites within CSF
inHIV-infected patients with andwithout tuberculousmeningitis
(TBM) and to evaluate the impact of pharmacogenetic variability
on drug disposition.
MATERIALS AND METHODS
Participants and sampling.TheCSFpharmacokinetics of EFVwere stud-
ied in two separate patient populations. Since these cohorts differ in sev-
eral characteristics, no statistical comparisons between the two groups
were undertaken.
(i) TBM group. In Vietnam, HIV-infected patients over 15 years of
age with newly diagnosed TBM (Clinical Trials Registration number
ISRCTN63659091) were randomized to receive immediate (within 7
days) or deferred (after 2 months) initiation of antiretroviral therapy as
previously described (21, 22). Among the subjects in this cohort, paired
CSF and blood samples were available at steady state for 47 subjects while
they were receiving EFZ (10 days) (23). Sampling was amean of 97 days
after the commencement of treatment. EFZ was dosed at 800mg together
with zidovudine plus lamivudine in a fixed-dose combination. Antituber-
culous therapy comprised isoniazid (5 mg/kg of body weight/day; maxi-
mum, 300 mg), rifampin (10 mg/kg/day; maximum, 600 mg), pyrazin-
amide (25 mg/kg/day; maximum, 2 g), and ethambutol (20 mg/kg/day;
maximum, 1.2 g) for 3 months, followed by isoniazid plus rifampin for 6
months. Unless contraindicated, all patients received dexamethasone as
described elsewhere (24). The mean age was 30 years (standard deviation
[SD], 5.4 years), and the median CD4 cell count at the time of sampling
was 81 cells/mm3 (interquartile range [IQR], 46 to 159 cells/mm3). All
patients were of Southeast Asian ethnicity. Ethics approval was obtained
from the Oxford Tropical Research Ethics Committee and the Hospital
for Tropical Diseases Scientific and Ethical Committee.
(ii) No-TBM group. In the United Kingdom, paired plasma and CSF
samples were obtained at a single time point from 25 subjects without
CNS infection from the United Kingdom PARTITION (Penetration of
Antiretroviral Therapy into the Nervous System) study (25). Participants
were HIV-1-infected adults (over 16 years of age) prospectively enrolled
from2 groups: those undergoing lumbar puncture for a clinical indication
or those with a history of unexplained intermittently or persistently de-
tectable plasmaHIV-1 RNAwithin the past 12months. In all patients, the
treating clinician believed that the CNS infection had been excluded on
the basis of CSF testing and clinical findings. All patients received 600 mg
of EFZ once daily; in 25 subjects, this was with tenofovir and emtricit-
abine, in 1 subject this was with lamivudine and abacavir, and in 1 subject
this was with darunavir and ritonavir. Themean age was 46 years (SD, 8.6
years), and the median CD4 cell count at the time of sampling was 432
cells/mm3 (IQR, 292 to 649 cells/mm3). Twenty (80%) subjects were of
white ethnicity, 3 (12%) were of black ethnicity, and 2 (8%) were of Asian
ethnicity. No subject was receiving antituberculous therapy or other en-
zyme-inducing medication at the time of sampling. The study was ap-
proved by the North Wales Research Ethics Committee (Central and
East).
EFZ and metabolite measurement. EFZ concentrations in plasma
and CSF samples from subjects receiving EFZ were determined at steady
state (10 days) (23), and samples were collected at amiddosing interval.
EFZmetabolite concentrations in a single pairedCSF-plasma samplewere
determined for each subject. Measurements were repeated with and with-
out -glucuronidase in the TBM group to determine the amount of
glucuronidated compound versus the amount of free compound. The
ratio between the albumin concentration in CSF and that in plasma or
serum was determined as a marker of blood-brain barrier integrity.
EFZ concentrations in plasma and CSF were measured by a validated
tandem liquid chromatography (LC)-mass spectrometry (MS)method as
previously described (26). Freshly prepared standards, quality control
samples (prepared in artificial CSF), and clinical samples (100 l) were
transferred into 7-ml stoppered glass tubes to which 100l of acetonitrile
was added. The samples were evaporated to dryness at room temperature
in a stream of nitrogen. The samples were then incubated at 37°C for 2 h
with 400 l of a solution containing 200 units of -glucuronidase from
Helix pomatia in 0.2 M sodium acetate buffer (pH 5) (27). The samples
were subsequently alkalinized with 20 l of potassium carbonate buffer
(0.1 M, pH 9.4) and extracted with 3 ml of a mixture of organic solvents,
ethyl acetate-hexane (60:40, vol/vol). After centrifugation, the organic
phase was evaporated to dryness, the residue was reconstituted in 100 l
of a mobile phase (50/50 [vol/vol] acetonitrile-H2O in 1mM ammonium
acetate), and 20l of this solutionwas analyzed directly by LC-MS/MS on
a Thermo Access triple-quadrupole mass spectrometer. Hexobarbital was
used as the internal standard. Gradient elution was on a reverse-phase C18
column using 1 mM ammonium acetate in water and acetonitrile. Quan-
tification was by selective reaction monitoring in the negative ionization
mode. Accuracy and precision were satisfactory, with amean bias of 4.8%
and an intra-assay coefficient of variability of 6.5%.
Albumin ratio. Albumin concentrations in CSF and blood (plasma/
serum) were determined by radial immunodiffusion (Bindarid). A CSF/
blood albumin ratio indicative of a breach in integrity of the blood-brain
barrier was taken to be6.8 for subjects less than 45 years old and10.2
for subjects over 45 years old (28).
Neurotoxic concentrations. The measured plasma and CSF concen-
trations were compared to the following concentrations associated with
neurotoxicity. Plasma EFZ concentrations of greater than 4,000 ng/ml are
associated with an increased risk of CNS side effects (8). Plasma EFZ
concentrations of less than 1,000 ng/ml have historically been associated
with virological failure (8). The concentrations of EFZ, 8OH-EFZ, and
7OH-EFZ associated with neuronal damage in vitro were 31.6, 3.3, and
33.2 ng/ml, respectively (20).
Genetic analysis.GenomicDNAwas purified fromwhole blood using
standard phenol-chloroform extraction methods. Allelic discrimination
was performed by TaqMan real-time PCR for determination of the
CYP2B6 c.516G¡T genotype and CYP2A6 copy number using validated
commercially available assays (Life Technologies, Paisley, United King-
dom).
Statistical analysis. The geometric mean log10 drug/metabolite con-
centrations were compared using Student’s t test and one-way analysis of
variance (ANOVA). The Pearson r coefficient was used to determine the
correlation between continuous variables. The CD4 count and CSF/
plasma ratio of the EFZ concentrationwere nonparametrically distributed
and analyzed using the Mann-Whitney U test. Fisher’s exact and chi-
Nightingale et al.
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square tests were used for categorical demographic data. All analyses were
performed using SPSS (version 22) software.
RESULTS
Plasma EFZ concentrations correlated with CSF EFZ concentra-
tions in both groups; however, there was no correlation between
plasma EFZ and CSF 8OH-EFZ concentrations (Fig. 1). The me-
dian ratio of the CSF/plasma EFZ concentration was 0.027 (IQR,
0.013 to 0.056) in the TBM group and 0.010 (IQR, 0.007 to 0.012)
in the no-TBM group.
CYP2B6 genotype. Forty-six samples from the TBM group
and 23 samples from the no-TBM group were successfully geno-
typed for CYP2B6 c.516G¡T (call rates, 98% and 88%, respec-
tively). Allele frequencies were 50% GG genotype, 43% GT geno-
type, and 7% TT genotype in the TBM group and 43% GG
genotype, 48%GT genotype, and 9%TT genotype in the no-TBM
group (Table 1). Only 5 patients had the TT (i.e., slow metabo-
lizer) genotype. CYP2B6 c.516G¡T was in Hardy-Weinburg
equilibrium in both groups (P  0.912 for the TBM group and
0.672 for the no-TBM group). The CYP2B6 c.516G¡T genotype
related to the concentration of EFZ in CSF and plasma in both
groups. This relationship was not present for the concentrations
of the 8OH-EFZ metabolite (Table 1). The concentrations of
7OH-EFZ in plasma and CSF were also not related to genotype.
There was no difference in the CSF/plasma EFZ concentration
ratio according to genotype. The effect of theCYP2B6 genotype on
EFZ and 8OH-EFZ concentrations with respect to the estimated
therapeutic range in plasma and the in vitro toxic concentrations
in CSF are shown in Fig. 2. The number and proportion of CSF
samples with concentrations above estimated in vitro toxic con-
centrations are given in Table 2.
Plasma EFZ concentrations were similar between the TBMand
no-TBM groups and mostly fell within the estimated therapeutic
range, regardless of genotype. CSF EFZ concentrations exceeding
the estimated in vitro neurotoxic level were observedmainly in the
TBM group, particularly in those with one or more CYP2B6
c.516G¡T mutations (i.e., those with the GT or TT genotype,
corresponding to intermediate or slow EFZ metabolizers, respec-
tively). CSF 8OH-EFZ concentrations tended to be above the es-
timated in vitro neurotoxic level in both groups regardless of ge-
notype.
CYP2A6 copy number variation. Forty-six samples in the
TBM group were successfully genotyped for the CYP2A6 copy
number (call rate, 98%). TheCYP2A6 gene deletion occurred in 8
(17%) subjects and was in Hardy-Weinburg equilibrium (P 
0.394). There was no association of the CYP2A6 copy number
with the concentration of EFZ or metabolites in plasma or CSF
either singly or in combination with the CYP2B6 genotype. A sin-
gle subject had the CYP2A6 gene deletion in combination with a
homozygous CYP2B6 c.516G¡T mutation; in this subject, the
EFZ concentration was 6,319.5 ng/ml in plasma and 54.7 ng/ml
in CSF.
Addition of-glucuronidase. In the TBMgroup, the addition
FIG 1 Relationship between concentrations of EFZ in plasma (a readily accessible and more easily measured parameter) and concentrations of EFZ and
8OH-EFZ in CSF. CSF and plasma EFZ concentrations were correlated in the TBMgroup (a) and the no-TBMgroup (b). No relationship was seen for 8OH-EFZ
in either the TBM group (c) or the no-TBM group (d). NS, not significant.
Pharmacokinetics of EFZ Metabolites in CSF
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of -glucuronidase did not significantly alter the concentrations
of EFZ (not tested in the no-TBM group, as the levels were much
lower). In contrast, the concentrations of 8OH-EFZ were much
higher following -glucuronidase addition. The ratio mean free/
total concentration of 8OH-EFZ was 0.064 in plasma and 0.075 in
CSF. Without -glucuronidase, free 8OH-EFZ concentrations
were low: mean concentrations were 87.3 ng/ml (95% confidence
interval [CI], 63.8 to 122.5) in plasma and 3.7 ng/ml (95% CI, 2.7
to 5.7) in CSF.
Mean 7OH-EFZ concentrations in the TBM group with
-glucuronidase were 75.3 ng/ml in plasma and 3.5 ng/ml in CSF;
without -glucuronidase, 7OH-EFZ levels were below the lower
limit of quantification. In the no-TBM group, mean 7OH-EFZ
concentrations were 236.6 ng/ml in plasma and 1.3 ng/ml in CSF.
Albumin ratio. The CSF/serum or plasma albumin ratio was
abnormal in 35 (90%) subjects in the TBM group and 4 (21%) in
the no-TBM group. In the TBM group, the CSF/plasma albumin
ratio was positively correlated with the CSF 8OH-EFZ concentra-
tion (Fig. 3c). A nonsignificant trend with the CSF EFZ concen-
tration was observed (Fig. 3a). In the no-TBM group, no correla-
tion between the CSF/serum albumin ratio and the CSF EFZ or
8OH-EFZ concentrations was observed (Fig. 3b and d).
DISCUSSION
Westudied the concentration of EFZ and itsmetabolites in plasma
and CSF and observed high CSF EFZ and 8OH-EFZ concentra-
tions in patients with TBM, which were not observed in those
without TBM. These differences could not have been explained by
the higher doses of EFZused in theTBMgroup (800mg versus 600
mg in the no-TBM group) since plasma exposures were compa-
rable across both study populations. We observed a strong corre-
lation between plasma and CSF EFZ concentrations, and both
were associated with the CYP2B6 c.516G¡T genotype. In con-
trast, the concentrations of the neurotoxic metabolite 8OH-EFZ
were not related to plasma EFZ concentrations or the CYP2B6
c.516G¡Tgenotype butwere correlatedwith the degree of blood-
brain barrier breakdown measured by the CSF/plasma albumin
ratio. These data confirm the findings of a recent publication from
the ENCORE CNS substudy which demonstrated an association
of the CYP2B6 c.516G¡T genotype with plasma and CSF EFZ
concentrations but not with plasma and CSF metabolite 8OH-
EFZ concentrations at doses of 400 mg and 600 mg (29). We
demonstrate the same relationship at an EFZ dose of 800 mg,
albeit when it is prescribed with rifampin, which induces the ac-
tivity of CYP2B6.
Themajority of EFZmetabolites in CSF were present as glucu-
ronide conjugates. This is less likely to be due to CSF trapping of
plasma glucuronide (the percentage of free compound was not
significantly higher in CSF) and suggests that EFZ metabolites
may be conjugated within the CNS. A number of UDP-glucu-
ronosyltransferases have been demonstrated to be present in hu-
man brain tissue (30, 31). EFZ metabolites may have entered the
CNS by crossing the blood-brain barrier or resulted from the CNS
metabolism of EFZ. Functional CYP2B6 and CYP2A6 are present
in the CNS, and expression has been shown to be inducible and
subject to genetic variation (32–34). The significance of the fact
that most 8OH-EFZ in CSF exists as a glucuronide conjugate is
unclear; in particular, it is not known whether glucuronidated
8OH-EFZ induces the same neurotoxic effects as free compound
or whether glucuronidation is in some way protective.We did notT
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measure glucuronidation in the no-TBMgroup; however, a recent
study in patients without TBM found similar high levels of 8OH-
EFZ glucuronidation in CSF (35).
This is the first report of EFZmetabolites in the CSF of patients
with TBM. CSF concentrations of EFZ and metabolites were
higher in those with a loss of blood-brain barrier integrity due to
TBM infection, and the concentrations were the highest in TBM
patients with the greatest loss of blood-brain barrier integrity, as
measured by the CSF/plasma albumin ratio. As EFZ is 99.75%
protein bound in blood (36, 37), higher CSF EFZ concentrations
may be due to leakage of the free fraction from plasma in those
with a loss of integrity of the blood-brain barrier or due to
increased trapping of EFZ in those with a higher albumin con-
centration in CSF.
TABLE 2 Proportion of CSF samples with EFZ and 8OH-EFZ
concentrations above in vitro toxic concentrationsa
Drug and
group
No. (%) of CSF samples from patients with the following
CYP2B6 c.516G¡T genotype:
All GG GT TT
EFZ
TBM 35 (76) 14 (61) 18 (90) 3 (100)
No TBM 3 (13) 0 (0) 2 (18) 1 (50)
8OH-EFZ
TBM 45 (98) 22 (96) 20 (100) 3 (100)
No TBM 20 (87) 10 (100) 9 (82) 1 (50)
a In vitro toxic concentrations are 31.6 ng/ml for EFZ and 3.3 ng/ml for 8OH-EFZ.
FIG 2 Effect of CYP2B6 genotype on estimated effective and toxic concentrations of EFZ in plasma (a and b), EFZ in CSF (c and d), and total 8OH-EFZ in CSF
(e and f). Error bars are geometric means and 95% confidence intervals for the GG/GT genotype and the geometric mean and range for the TT genotype. MTC,
minimum toxic concentration; MEC, minimum effective concentration; ITC, in vitro toxic concentration.
Pharmacokinetics of EFZ Metabolites in CSF
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CSF EFZ concentrations consistently exceeded in vitro neuro-
toxic concentrations in patients with a combination of TBM in-
fection and the CYP2B6 c.516G¡T mutation (i.e., those with the
GT or TT genotype, corresponding to intermediate or slow EFZ
metabolizers, respectively). In contrast, CSF total 8OH-EFZ con-
centrations exceeded the in vitro neurotoxic concentration in the
majority of subjects with and without TBM, regardless of geno-
type. This has implications for neuronal damage in patients with
TBM, which could contribute to the overall neurological sequelae
from this disease. Data from the recent ENCORE CNS substudy
demonstrated an association of CSF 8OH-EFZ concentrations
with symptoms at 1 year (29). The main limitation of our study is
that we could not examine whether potentially neurotoxic CSF
concentrations corresponded to clinical evidence of neurological
dysfunction. There are several reasonswhy this was the case. In the
TBM group, adverse neurological outcomes were attributed to
TBM rather than drug neurotoxicity. Higher albumin ratios may
reflect more severe TBM infection and, hence, confound any as-
sociation of CSF 8OH-EFZ with clinical outcomes. The albumin
ratiowould be expected to decrease over time,whichmay coincide
with clinical improvements. In the no-TBM group, detailed cog-
nitive testing was not performed, and most patients in that group
had a clinical indication for lumbar puncture which may have
confounded associations with clinical outcomes. Further work is
needed to determine the short- and long-term clinical conse-
quences related to CSF 8OH-EFZ concentrations far exceeding in
vitro neurotoxic levels, as this has important clinical implications.
One question is whether EFZ should be avoided in those with
impaired blood-brain barrier integrity, in particular, those with a
neurological infection, such as TBM. However, as discussed
above, such studies will be limited by difficulties in separating EFZ
neurotoxicity from the effects of neurological infection. Another
question is whether CYP2B6 c.516G¡T genotyping in clinical
practice would lower the incidence of neurocognitive side effects.
Our data suggest that avoiding EFZ in those with the GT or TT
genotype would not alter CSF 8OH-EFZ concentrations and,
hence, may not be an effective strategy.
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